CG Oncology, Inc. Form 10-K Summary
Business Context and Reporting Period
CG Oncology is a clinical-stage biopharmaceutical company focused on cretostimogene, an investigational intravesical oncolytic immunotherapy for bladder cancer. The filing covers the fiscal year ended December 31, 2023. The company has no approved products, no product sales, and depends substantially on the successful development and approval of cretostimogene.
The lead program is BOND-003, a completed-enrollment Phase 3 trial in high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The company reported interim data in November 2023 and expects topline data by the end of 2024. Additional programs include CORE-001, a Phase 2 combination trial with pembrolizumab; PIVOT-006, a Phase 3 trial in intermediate-risk NMIBC initiated in November 2023; planned CORE-008; and the investigator-sponsored CORE-002 trial in muscle-invasive bladder cancer.
Financial and Liquidity Overview
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Research and collaboration revenue | $0.2 million | $0.2 million | +$0.01 million |
| Research and development expense | $45.8 million | $29.0 million | +$16.7 million |
| General and administrative expense | $9.9 million | $6.4 million | +$3.5 million |
| Total operating expenses | $55.7 million | $35.4 million | +$20.2 million |
| Loss from operations | $(55.4) million | $(35.2) million | $(20.2) million |
| Other income, net | $6.8 million | $(0.2) million | +$7.0 million |
| Net loss | $(48.6) million | $(35.4) million | $(13.2) million |
| Net loss attributable to common stockholders | $(67.8) million | $(43.8) million | $(24.0) million |
| Basic and diluted loss per share | $(15.65) | $(11.71) | $(3.94) |
Revenue remains immaterial relative to expenses, so product-level margins are not meaningful. The company used $45.7 million of cash in operating activities, compared with $29.8 million in 2022. Investing activities used $121.2 million, primarily reflecting purchases of marketable securities. Financing activities provided $87.0 million, including $104.6 million of net Series F preferred-stock proceeds, partly offset by $16.3 million of debt repayment and $3.4 million of deferred IPO costs.
At December 31, 2023, cash and cash equivalents were $8.3 million, marketable securities were $179.4 million, and total current assets were $194.1 million. Total liabilities were $14.5 million. The company had no outstanding term debt at year-end after repaying its Silicon Valley Bank loan in May 2023, although a $0.4 million success fee was paid in March 2024. Management estimated that year-end cash, cash equivalents, and marketable securities would fund operations through 2027, subject to assumptions that may prove incorrect.
The company subsequently completed its initial public offering in January 2024, selling 23.0 million shares at $19.00 per share and receiving approximately $400.4 million in net proceeds. Preferred stock converted into common stock in connection with the IPO.
Material Changes Versus the Prior Comparable Period
- R&D expense increased 58%, primarily because of higher clinical-trial, contract research organization, CMC, consultant, and personnel costs.
- G&A expense increased 55% due largely to higher headcount, professional fees, and public-company preparation costs.
- Operating cash burn increased to $45.7 million from $29.8 million.
- Interest income increased to $6.9 million from approximately breakeven, reflecting larger invested cash and marketable-security balances.
- The company raised approximately $105.0 million gross through its Series F preferred-stock financing and repaid its term loan.
- BOND-003 completed enrollment, PIVOT-006 was initiated, and the company expanded its clinical development plans.
- Headcount increased to 61 full-time employees at year-end, including 44 in research and development.
Clinical Outlook, Commentary, and Risks
Interim BOND-003 data as of October 5, 2023 showed a complete response in 50 of 66 evaluable patients, or 75.7%, at any time; 68.2% at three months; and 63.6% at six months. Among responders, 74.4% of evaluable patients maintained a response for at least six months. The company reported no Grade 3 or higher treatment-related adverse events, no treatment-related discontinuations, and no deaths as of the reported safety cutoff. These are interim, single-arm results and may change as additional data mature.
In CORE-001, 29 of 34 evaluable patients, or 85%, achieved a complete response at any time as of March 3, 2023; 82% maintained a response at six months and 68% at 12 months. Pembrolizumab-related serious adverse events and discontinuations were reported. In CORE-002, eight of 15 evaluable patients achieved a pathological complete response as of March 31, 2023.
Cretostimogene has received FDA fast track designation and, according to the filing, Breakthrough Therapy designation for specified NMIBC indications. Regulatory approval is not assured. The company has not yet completed a pivotal trial, submitted a BLA, or commercialized a product.
- The company depends almost entirely on one product candidate and expects continuing losses and negative operating cash flow.
- Clinical results are interim and from relatively small, open-label or single-arm studies; later-stage results may differ materially.
- Regulatory, manufacturing, enrollment, safety, comparability, and supply-chain risks could delay or prevent approval. The company relies on third-party manufacturers and has no long-term supply agreements or redundant manufacturing arrangements.
- The company currently lacks commercial sales, marketing, distribution, and commercial manufacturing capabilities.
- Market acceptance, reimbursement, pricing, competition, and any increase in BCG supply could reduce the commercial opportunity.
- Intellectual-property protection is limited in certain respects, including the absence of composition-of-matter patents covering cretostimogene as disclosed in the filing.
- ANI Pharmaceuticals filed a March 4, 2024 lawsuit seeking a declaration that a 2010 agreement requires CG Oncology to pay a 5% royalty on worldwide net sales of cretostimogene. The company disputes the claim; the potential financial exposure is not clearly quantifiable from the filing.
- The company’s ability to use its tax attributes may be limited by prior or future ownership changes.
Important Facts for Investors to Verify
- Final BOND-003 topline results, durability of response, safety, and the FDA’s position on a potential BLA filing.
- Whether PIVOT-006 enrollment and CORE-008 initiation proceed on the stated timelines.
- Cash burn, clinical-trial spending, and whether the stated funding runway through 2027 remains achievable after the IPO and expanded programs.
- Manufacturing comparability, third-party capacity, long-term supply agreements, and cold-chain reliability.
- The status and potential royalty consequences of the ANI Pharmaceuticals litigation.
- Conversion effects, option dilution, lock-up expirations, and registration rights following the January 2024 IPO.
- Future reimbursement, competitive developments, BCG supply trends, and the regulatory status of competing NMIBC therapies.